|
At the 95th annual American Association for Cancer Research (AACR) meeting in Orlando USA AstraZeneca Plc reported new gefitinib (IRESSA(tm) ZD1839) data exploring mechanisms of drug activity and resistance as well as new data relating to novel anti-angiogenesis drugs ZD6474 and AZD2171 that have potential in a wide range of tumors.
|